Ocriplasmin, a truncated form of plasmin, is commercialized in the USA and in Europe under the trade name Jetrea w , and indicated for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction including when associated with macular hole 400 mm, respectively. We have shown in a previous study that ocriplasmin undergoes autolytic degradation when injected in eye vitreous, which leads to its rapid inactivation. In order to investigate this process further, we have introduced in ocriplasmin a variety of amino acid substitutions within or in the immediate vicinity of the three major autolytic cleavage sites. We demonstrate here that autolytic inactivation of ocriplasmin is a sequential process where initial cleavage occurs primarily between residues 156 and 157. Reduction or even blocking of autolysis can be achieved by mutating a limited number of key residues. In this study, we also report the identification of a series of ocriplasmin variants with improved resistance to autolysis and unimpaired catalytic activity. Such variants represent useful tools for the exploration of therapeutic approaches aiming at non-surgical resolution of vitreomacular adhesion.
Introduction
Ocriplasmin (des-kringle 1-5 plasmin, also known as microplasmin, brand name Jetrea w ) is an approved drug for the treatment of symptomatic vitreomacular adhesion (VMA) in the USA, and in the European union for the treatment of vitreomacular traction (VMT), including when associated with macular hole 400 mm (Stalmans et al., 2012) . Anomalous VMA is a condition where age-related posterior vitreous detachment (PVD) is incomplete. Traction on the retina caused by incomplete PVD can induce visual distortions (metamorphopsia) and, in more severe cases, macular holes leading to potentially permanent loss of vision.
Until the approval of ocriplasmin, symptomatic VMA (or VMT) was treated by a surgical procedure known as vitrectomy. This procedure however bears the risk of damage to the retinal surface or the optical nerve head (Vander and Kleiner, 1992; Han et al., 1998) , which explains why a number of proteolytic enzymes, including plasmin, have been tested for enzymatic (rather than surgical) release of retinal traction (Sebag, 1998; Trese, 2000 Trese, , 2002 Bhisitkul, 2001) .
Ocriplasmin was developed for therapeutic use in the early 2000s as a substitute for plasmin, for which recombinant expression proved difficult (Whitefleet-Smith et al., 1989; Aerts et al., 2012) . Manufacturing challenges were overcome by the expression of the inactive zymogen in the methylotrophic yeast Pichia pastoris followed by activation by recombinant staphylokinase and formulation as a stable product. Despite lacking all five kringle domains, ocriplasmin exhibits intact catalytic activity (Wu et al., 1987) , and clinical trial studies have demonstrated that retinal traction in symptomatic VMA patients can be released by a single, intravitreal dose of ocriplasmin (de Smet et al., 2009; Benz et al., 2010; Stalmans et al., 2012; and TG-MV-006 and TG-MV-007 clinical trials).
In its active form, ocriplasmin consists of two polypeptides of 19 and 230 residues connected by two disulfide bonds, the 230-residue domain being further stabilized by four intrachain disulfide bonds (Fig. 1) . Although stable under its formulation conditions, ocriplasmin is rapidly inactivated in neutral-pH buffers and in vitreous. We have demonstrated elsewhere that inactivation of ocriplasmin follows second-order kinetics and is caused by autolytic degradation (Aerts et al., 2012) . Using a combination of N-terminal sequencing and mass spectrometry, we identified three autolytic cleavage sites in the 230-residue domain. Here, we describe a series of ocriplasmin variants obtained by the introduction of single-point mutations. Our data allowed us to confirm the identity of the autolytic cleavage sites and to further validate the existence of a sequential inactivation mechanism. We also report the identification of ocriplasmin variants which combine remarkable resistance to autolytic inactivation with unimpaired catalytic activity.
Materials and methods

Preparation of expression vectors
The pPICZaA secretion vector (Life Technologies) was used for the expression of recombinant human microplasminogen (the inactive precursor of ocriplasmin) and microplasminogen variants in P. pastoris (strain X33). The genes encoding the different proteins were obtained by de novo synthesis after codon optimization for P. pastoris expression and removal of 6 bp palindromic sequences and nucleotide repetitions. Codon optimization was performed using Gene Designer (DNA2.0, Menlo Park, CA, USA). In some cases, microplasminogen variants were obtained after site-directed mutagenesis on expression vectors prepared as described above using the QuikChange II Site Directed Mutagenesis Kit (Agilent Technologies).
Production and purification of ocriplasmin variants
The protocol for expression of the microplasminogen variants was essentially derived from the EasySelect TM Pichia Expression Kit manual (Life Technologies, Cat. K1740-01). Briefly, 200 ml of buffered glycerol-complex medium supplemented with 100 mg/ml Zeocin were inoculated with a single P. pastoris clone, and the culture was allowed to grow at 308C for 24 h. The absorbance at 600 nm (OD 600 ) was then measured, and the cells were collected by centrifugation from a volume of culture corresponding to 400 ml with an OD 600 ¼ 1. The cell pellet was resuspended in 400 ml of buffered methanol-complex medium supplemented with 100 mg/ml Zeocin, and the culture was incubated at 308C for 48 h with an addition of 4 ml of methanol after 24 h. At this stage, the supernatant was collected by centrifugation and supplemented with 8 ml of 0.5 M ethylenediaminetetraacetic acid. The microplasminogen variants were purified by immunoaffinity from the culture supernatants using Sepharose beads coupled to a murine, monoclonal anti-ocriplasmin antibody (clone 7H11A11 or 5D10D4) raised in Balb/c mice. Crude supernatants were passed through a 0.2 mm filter and directly loaded on the affinity column. After washing with 100 mM KH 2 PO 4 , 0.5 M NaCl, pH 6.2, the microplasminogen variants were eluted with 0.2 M glycine-HCl, pH 3.0, and the collected fractions were immediately neutralized and dialyzed against 25 mM sodium phosphate, pH 7.2.
Activation of ocriplasmin variants and measure of the rate of autolytic inactivation
The purified microplasminogen variants were converted into the respective active ocriplasmin species using either urokinase (Sigma) or recombinant staphylokinase SAK-SY162 (a variant of the staphylokinase Sak-STAR (Collen et al., 1992) with the following amino acid substitutions: K35A, E65Q, K74R, E80A, D82A, T90A, E99D, T101S, E108A, K109A, K130T and K135R). The microplasminogen variants (typically 5 -20 mM) were incubated at 378C in the presence of urokinase (typical microplasminogen/ urokinase ratio ¼ 200/1) or staphylokinase (typical microplasminogen/staphylokinase ratio ¼ 50/1), and the appearance of the active ocriplasmin species was followed by monitoring the hydrolytic activity against the chromogenic substrate S-2403 (Glu-Phe-Lys-pNA) as previously described (Aerts et al., 2012) . Once maximal activity was reached, the extent of microplasminogen conversion was assessed by sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS -PAGE) and high-performance liquid chromatography (HPLC) using a methodology also described by Aerts et al.
Following activation, the autolytic reaction was monitored by measuring the loss of activity in the sample maintained at 378C. Buffer composition was as indicated above, i.e. 25 mM sodium phosphate, pH 7.2. Autolytic degradation was also visualized by SDS-PAGE and HPLC. The determination of the second-order rate constant for autolysis (k) was determined as follows: (i) the area of the peak in HPLC corresponding to the active ocriplasmin species was used to calculate the concentration of this particular species at the end of the activation phase by comparison with a standard curve established using clinical-grade ocriplasmin; (ii) the loss of activity measured during the autolytic phase was used to calculate for each time point the residual concentration of the active species; (iii) the residual concentration (in mol/l) of the active species was plotted as a function of time (expressed in s), and Eq. (1) was fitted to the data with the help of the GraphPad Prism software (GraphPad Software Inc., La Jolla, CA, USA) to obtain an autolysis constant k, the value of which is expressed in M 21 s
21
. In Eq. (1), [OPL] is the concentration of ocriplasmin at any given time and [OPL] 0 the concentration of ocriplasmin at t ¼ 0.
In order to measure the rate of autolysis in vitreous humor, the active form of some ocriplasmin variants was prepared using a methodology similar to the one used to prepare clinical-grade ocriplasmin (see Aerts et al., 2012) . The rate of autolysis in homogenized porcine vitreous was then measured as previously described (Aerts et al., 2012) .
Determination of the kinetic parameters k cat and K m
The microplasminogen variants preparations were first activated with staphylokinase or urokinase, and the concentration of the active species was determined at the end of the activation phase as described above. However, in order to prevent subsequent inactivation, the samples were stabilized by lowering the pH to 3 by addition of two volumes of 5 mM citric acid. The kinetic parameters of the ocriplasmin variants against the chromogenic substrate S-2403 were then obtained by measuring initial rates of hydrolysis at various substrate concentrations, the conditions of the assay being those described earlier (Aerts et al., 2012) . The k cat and K m parameters were computed from non-linear regression analysis using Eq. (2), where [OPL] is the concentration of active ocriplasmin as measured by HPLC, and [S] is the concentration of S-2403. Alternatively, k cat /K m values were determined from the analysis of total hydrolysis curves obtained at [S] ,, K m with Eq. (3), where A t , A 0 and A 1 represent the absorbance at times t ¼ t, t ¼ 0 and t ¼ 1. Fitting analyses were performed with the help of the GraphPad Prism software. Measurements were performed at 378C in 50 mM Tris-HCl, 38 mM NaCl, 0.01% Tween-80, pH 7.4.
N-terminal sequencing N-terminal sequencing of bands excised from SDS-gels was performed by Eurosequence B.V. (Groningen, The Netherlands).
Molecular modeling
In order to investigate the three-dimensional (3D) environment of a key residue in this study (Glu 157), the protein databank (Berman et al., 2000) was searched for relevant structures. From the available structures, 1QRZ (catalytic domain of plasminogen) and 1BML (catalytic domain of plasmin) were selected as representative, based on best refinement, resolution and the presence of water molecules (Wang et al., 1998; Peisach et al., 1999) . Mutation (Glu 157!Gln) and energetic calculations were performed using the Brugel package (Delhaise et al., 1988) . This package uses a CHARMM force field to calculate interactions (Brooks et al., 1983) . The orientation of the side chain of the Gln 157 mutant was modeled using the best rotamer in the dead-end elimination method (Desmet et al., 1992) . Figures were created with Pymol (The PyMOL Molecular Graphics System, version 1.5, Schrödinger, LLC).
Results
Autolytic cleavage of ocriplasmin occurs between residues K156-E157, K166-V167 and R177-V178, in agreement with the substrate specificity of ocriplasmin, known to cleave downstream of positively charged lysine or arginine residues (Aerts et al., 2012) . We therefore first chose to produce and characterize a series of variants of ocriplasmin harboring mutations at positions 156, 166 and 177. Position 157 was also investigated for reasons given below. The mutations were looked at either individually or in combination, and the variants were characterized both in terms of catalytic activity and in terms of resistance to autolytic degradation.
Production, purification and characterization of ocriplasmin variants
Ocriplasmin variants were produced in P.pastoris in the inactive zymogen form. Following affinity purification, the zymogen forms were converted into catalytically active forms using either staphylokinase or urokinase. The rate and extent of the conversion into the active form was followed by monitoring the activity of aliquots collected at various times. Typically, under the experimental conditions used here, the activity reached a maximum after 5 -10 min, although the activation of some mutants was significantly slower. The time point where the activity reached a maximum indicated maximal conversion of the zymogen. From there on, autolytic degradation would cause the activity to decrease. Importantly, experimental data were generated in such a way that activation occurred on a much shorter timescale than autolysis, and the data used for the calculation of the autolysis rate constants were those obtained after conversion of the zymogen into the active form was maximal, in such a way that the two processes overlapped minimally. An example of such an activation curve is shown in Fig. 2A for the K156M variant. SDS-PAGE and HPLC were used to evaluate the extent of activation (Figs. 2B and C). HPLC was also used to measure the concentration of the active species at the beginning of the inactivation phase (Fig. 2C) . Combined with this information, analysis of the inactivation phase using a model describing second-order kinetics allowed the calculation of the second-order rate constant for the autolytic inactivation process (Fig. 2D) . Aliquots collected throughout the inactivation phase were also analyzed both by HPLC and SDS-PAGE to monitor and characterize the accumulation of the autolytic degradation species (Figs. 2C and D) . Finally, N-terminal sequencing of bands extracted from SDS -gels was used in specific cases for the identification of the cleavage site.
In parallel with this, an aliquot collected at the time where the activity reached a maximum value was used to measure the kinetic parameters k cat and K m against the chromogenic substrate S-2403 (Fig. 2E) . Reducing SDS-PAGE showing that activation with staphylokinase is nearly complete within 10 min, and that loss of activity results from autolytic degradation, as evidenced by the accumulation of two fragments of 17 and 8 kDa. Lanes 1 -6 represent samples collected 0 min, 10 min, 1 h, 2 h, 3 h and 6 h after addition of staphylokinase. Black up-pointing triangle, microplasminogen; black down-pointing triangle, ocriplasmin; empty inverted triangle, autolytic degradation fragments. (C) HPLC profiles of samples collected 0 min, 10 min and 6 h after addition of staphylokinase. The HPLC profile obtained 10 min after addition of staphylokinase indicates that 85% of the inactive microplasminogen has been converted into the active ocriplasmin species, and the HPLC profile at t ¼ 6 h shows the presence of the autolytic degradation fragments (empty inverted triangle), in agreement with the SDS-gel shown in (B). The ocriplasmin peak area at t ¼ 10 min (arrow) was used to calculate the concentration of the active species by comparison with a standard curve established with highly purified ocriplasmin. (D) The quantification of the active K156M species at t ¼ 10 min by HPLC and the subsequent decrease in residual activity were combined to calculate the molar concentration of the active species at each time point. Equation (1) was fitted to the data to calculate the second-order rate constant for autolysis (k) . The open circles represent the data for the K156M variant. For comparative purposes, a similar set of data obtained with another variant (K166A-R177A) is also represented (filled circles). The data represent the average of duplicate measurements. (E) Determination of k cat and K m from the measurement of initial rates of hydrolysis (v i , average of duplicate measurements) at different substrate (S-2403) concentrations. Equation (2) was fitted to the data.
Single-point mutations at positions 156, 166 and 177
A series of substitutions (6 -7 at each position) were introduced at positions 156, 166 and 177. All variants could be isolated from Pichia supernatants with a yield similar to the one observed for wild-type ocriplasmin under the same conditions, suggesting that none of the substitutions introduced major stability and/or folding constraints.
Activity and autolytic inactivation data for wild-type ocriplasmin and all mutants at positions 156, 166 and 177 are summarized in Table I . It should be noted here that the data reported for wild-type ocriplasmin were obtained with material produced with the same procedure as the one used to generate the variants. The autolysis rate constant found here (230 M 21 s
21
) was in excellent agreement with the one reported in our previous study using clinical-grade ocriplasmin (i.e. 176 M 21 s
), despite slight differences in the experimental conditions (25 mM sodium phosphate, pH 7.2 in the present study vs. phosphate-buffered saline in our previous study). Activity data reported here were also in good agreement with those obtained with clinical-grade ocriplasmin (k cat ¼ 47 s
, K m ¼ 58 mM) and, importantly, were also very close to those obtained for the full-length plasmin (k cat ¼ 50 s 21 , K m ¼ 110 mM). All variants with a substitution at position 156 turned out to be significantly more resistant to autolytic degradation than wild-type ocriplasmin, k values ranging from 1 to 10 M 21 s
. In all cases however, accumulation of autolytic degradation fragments was confirmed by HPLC and SDS -PAGE analyses. All of the K156 variants exhibited a marked increase in their K m values, leading to a decreased catalytic efficiency (as defined by the k cat /K m ratio). This was true also when Lys 156 was substituted by an Arg residue. The K156E variant also exhibited a 10-fold decrease in its k cat value. N-terminal sequencing of bands extracted from an SDS-gel for the K156Q mutant confirmed cleavage between positions 166-167 and 177-178.
Substitutions at positions 166 and 177 led to less dramatic changes. Activity of all mutants was essentially preserved or only minimally affected. The rate of autolysis, in contrast, was affected by up to a factor 10 for mutations at position 166 and up to a factor 3 -4 for mutations at position 177. Some mutations (most notably substitutions of Lys 166 and Arg 177 by Phe or His residues) only led to a marginal decrease in the rate of autolysis (Table I) .
The cleavage sites for the K166H mutant were identified by N-terminal sequencing to be between positions 156 -157 and 177 -178, as expected. The same analysis performed for the R177H mutant revealed a major cleavage site C-terminal of Lys 166. Cleavage downstream of Lys 156 could not be directly confirmed. However, in the light of the data presented in this manuscript, it is reasonable to assume that this is because the corresponding product did not accumulate sufficiently, rather than because cleavage did not occur. By contrast, though, a sequence corresponding to a low-abundance product showed the existence of a minor cleavage site between Arg 170 and Tyr 171 that had not been identified in wild-type ocriplasmin.
Double and triple mutations at positions 156, 166 and 177
Ocriplasmin variants harboring either two or three mutations at positions 156, 166 and 177 were prepared in a similar way as the single mutants. Here too, the mutations were well tolerated from a stability/folding point of view. The kinetic parameters and the autolytic degradation rate constant for these mutants are listed in Table I . It can be seen from these data that the effect of mutations at the three positions studied here were essentially additive.
Mutating both Lys 166 and Arg 177 resulted in a relatively limited impact on the activity and the rate of autolysis. This was particularly true for the K166H-R177H double mutant, whose rate constant for autolysis differed by less than a factor of 2 compared with wild-type ocriplasmin. By contrast, all double or triple mutants with mutations at position 156 were characterized by a severely impaired catalytic efficiency resulting from an increased K m , and by a greater resistance to autolysis. Species resulting from the autolytic degradation process were however detected by SDS-PAGE and HPLC for all double mutants. N-terminal sequencing revealed that autolytic cleavage in double mutants occurred at the level of the position that was not mutated, i.e. 156, 166 and 177 for the 166/177, 156/177 and 156/166 double mutants, respectively. The absence of autolytic degradation species was observed only in the triple mutants, with the exception of the K156R-K166H-R177H mutant, for which autolytic cleavage, presumably occurring C-terminal of Arg 156, was detected. For these mutants, it should be understood that the k value reported in Table I reflects the overall stability of the protein under the experimental conditions used here rather than the rate of the autolytic process.
Mutations at position 157
We have shown above that autolysis of ocriplasmin can be efficiently blocked by mutating the positively charged residues (Lys or Arg) in each of the three main autolytic cleavage sites. However, any substitution of Lys 156 resulted in a dramatic increase in K m and a corresponding decrease in the catalytic efficiency, which considerably limits the biological value of these variants. We therefore explored mutations in the immediate vicinity of position 156 in the hope of identifying variants with increased resistance to autolysis and unimpaired activity. Following this approach, we found that such a variant could be obtained by replacing glutamate 157 by a glutamine residue. The corresponding E157Q mutant displayed an unaltered proteolytic activity while exhibiting an almost 60-fold decrease in the rate of autolytic inactivation (k for autolysis ¼ 4 M 21 s
21
). The Glu 157!Gln substitution was also successfully combined with a Lys 166!Glu mutation, the resulting mutant exhibiting an additional, 2-fold decrease in the rate of autolysis (Table I) .
It cannot be excluded that substitution of Glu 157 by a Gln residue renders this particular stretch of sequence intrinsically less susceptible to autolytic cleavage. Intriguingly however, and despite the large difference in the rate of autolysis between the wild-type enzyme and the E157Q mutant at neutral pH, these two proteins displayed very similar properties at pH 4.4 (k for autolysis ¼ 1.3 and 2.5 M 21 s 21 for the wild-type enzyme and the E157Q mutant, respectively). An interesting explanation is that the carboxylic group of the Glu 157 side chain in the wildtype enzyme is protonated at pH 4.4 but unprotonated at neutral pH, and that the presence of the negative charge at neutral pH is responsible for local electrostatic destabilization that increases the sensitivity of this particular area of the protein to autolytic cleavage. It is indeed striking that the 156-157 peptide bond, unlike those of the other cleavage sites reported here, is buried in the interior of the protein, and we have already hypothesized that autolytic inactivation of ocriplasmin requires at least local or partial unfolding (Aerts et al., 2012) . This led us to examine the available X-ray structures for the catalytic domain of plasminogen and plasmin (1QRZ and 1BML, respectively). In the plasminogen structure, the Glu 157 side chain is electrostatically well-stabilized with a double hydrogen bond from its side chain atoms OE1 to W31 and a water molecule, and OE2 to the main chain amide hydrogens of C16 and K15, as can be seen in Fig. 3B . Upon activation, the peptide bond between R19 and V20 is broken. We found that this results in a more flexible structure (while the B-factors for both backbone structures are comparable, the relative higher B-factors of the 1-19 peptide backbone segment is indicative of a relative higher flexibility). Also, we observed that in the active catalytic domain, the carboxylic group of Glu 157 points into the direction of the main chain carbonyl of K15 (Fig. 3C ). As such, the proximity of the negative charge of the Glu 157 carboxylic group and the partial negative charge of the main chain carbonyl of Lys 15 forms an electrostatic environment that is less favorable compared with the inactive plasminogen state. The E157Q mutation restores a more favorable electrostatic environment (Fig. 3D) . We calculated (using the CHARMM force field, see the Materials and methods section) that the energetics of this unfavorable interaction is 2.8 kcal/mol. This value is in agreement with the DDG value of 2.4 kcal/mol calculated from the reduction in the rate of autolysis using Eq. (4) (where k E157Q and k WT are the rates of autolysis at neutral pH for the E157Q and the wildtype enzymes, respectively). This equation was described previously in the context of stabilization by sugars (Aerts et al.,  2012) , and derives from a two-step model originally proposed by Stoner et al. (2004) where the native state of the protein is in equilibrium with the unfolded protease, and where the unfolded species is cleaved by a native molecule. Indirectly, this model thus allows calculating changes in the thermodynamic stability of the protein through measurements of the rate of autolysis. This analysis therefore suggests that the increased resistance to autolytic inactivation of the E157Q mutant originates from the stabilization of the area of the protein that is sensitive to autolysis.
Autolytic degradation of ocriplasmin follows an ordered, sequential process
The data summarized in Table I indicate that mutations at positions 166 and 177 have only a limited impact on the rate of autolysis of ocriplasmin. By contrast, mutating Lys 156 or rendering the 156 -157 peptide bond less susceptible to autolytic cleavage by substituting Glu 157 by a glutamine led to a spectacular increase in the resistance to autolytic inactivation. This suggests that autolysis of ocriplasmin is not a random process, but rather that it follows a kinetically controlled, sequential mechanism where cleavage occurs first at position 156 -157, downstream cleavage at positions 166 -167 and 177 -178 occurring after the initial cleavage.
Interestingly, examination of the autolytic process using HPLC already led us to hypothesize that autolysis of ocriplasmin follows a sequential process (Aerts et al., 2012) . We therefore decided to explore this further by following the autolytic inactivation of ocriplasmin at various pHs. The rational here was that by lowering the hydrolytic activity of ocriplasmin (which is pH-sensitive, and in particular decreases at acidic pH), we would be able to 'trap' and characterize species representing intermediate steps in the autolysis reaction. This experiment is presented in Fig. 4 . N-terminal sequencing of bands extracted from SDS -gels showed that cleavage is restricted to position 156 -157 at pH 4.1, but proceeds subsequently to positions 166 -167 and then 177 -178 when the pH is raised to 4.5 and then to 5.1.
Behavior of ocriplasmin variants in vitreous humor
The vitreous humor is the transparent gel substance that fills the space between the lens and the retina. We have demonstrated in a previous study that ocriplasmin inactivates in vitreous via the same autolytic mechanism as the one happening in neutral-pH solutions (Aerts et al., 2012) , and therefore ocriplasmin autolytic-resistant species, such as the E157Q variant, may be used in vivo to explore the influence of autolysis on therapeutic efficacy. In order to further validate this concept, we measured the rate of autolysis of the E157Q, K166E and K166Q variants in porcine vitreous. These data are also included in Table I . Although rates of autolysis, as reported in Autolytic degradation of ocriplasmin our previous study, are somewhat lower in vitreous, our data show that the general properties of the variants reported here can be extrapolated in vitreous, the E157Q variant exhibiting under these conditions too a much higher stability than the wild-type enzyme.
Discussion
Ocriplasmin represents the first non-surgical alternative to vitrectomy for the treatment of symptomatic VMA or VMT. Its natural susceptibility to autolytic inactivation however complicates handling and storage, and may also influence its efficacy in vivo.
Three main autolytic cleavage sites have been identified in ocriplasmin. These cleavage sites are located in the same vicinity (Fig. 3) , in an area of the protein that therefore seems to represent its Achilles' heel. An approach was therefore undertaken with the objective of delineating the autolysis process. Each of the three cleavage sites identified previously, namely 156-157, 166 -167 and 177 -178, was submitted to extensive mutational analysis. While mutating positions 166 and 177 resulted in only a moderate impact on the rate of autolysis, substitution of Lys 156 led to both a marked increase in the kinetic parameter K m and a corresponding decrease in the catalytic efficiency k cat /K m , and a significant reduction in the rate of autolysis. The effect of mutations at these positions was essentially additive, and autolytic inactivation could be efficiently blocked in the 156 -166-177 triple mutants. Analysis of double-mutants-156 -166, 156-177 and 166-177-also revealed that any one of these three sites is susceptible to cleavage irrespective of whether the two other sites are intact or not, and that cleavage at any of these three sites results in an inactive molecule.
Our data also point towards a sequential mechanism in which autolytic cleavage occurs first at position 156-157. The fact that autolytic degradation is not completely abolished in the 156 variants indicates, however, that the control of the order of cleavage is kinetic rather that mechanistic, i.e. that initial cleavage occurs at position 156 -157 because it is faster and not because cleavage at position 156 -157 is a prerequisite for cleavage at other positions (166 -167 and 177 -178) . Nevertheless, given that a species where cleavage at position 156-157 has occurred is inactive, and that extensive cleavage at position 177 -178 is observed in wild-type ocriplasmin (Aerts et al., 2012) , it must be concluded that cleavage at position 156 -157 greatly enhances the susceptibility of the other two sites to autolytic cleavage.
The reason why the 156-157 position is the primary autolytic cleavage site in ocriplasmin remains however unclear. There is no common pattern around the cleavage sites and, as reported previously, the P4-P3-P2 sequences of all three identified cleavage sites differ from the optimal sequence specificity determined for plasmin (Aerts et al., 2012) . In addition, the accessibility to the solvent is only 4% for K156, vs. 70% for K166 and R177, suggesting that susceptibility of potential cleavage sites is greatly determined by local structural motion.
In conclusion, we describe here ocriplasmin variants with unimpaired hydrolytic activity and improved resistance to autolytic inactivation. Some variants are only marginally more stable than wild-type ocriplasmin, while others exhibit inactivation rate constants 50-to 100-fold lower than the one of the wild-type protein. In many of these variants, the autolytic cleavage sites were eliminated by mutating the positively charged residue (Lys or Arg) in the P1 position. Interestingly, the increased resistance to autolysis of the E157Q variants seems to proceed from a local stabilization of the 3D structure. Without being an entirely new concept (e.g. protein stability/flexibility has been correlated with sensitivity to autolysis (Veltman et al., 1996 (Veltman et al., , 1997 , proteolysis (Daniel et al., 1982; Frenken et al., 1993; Akasako et al., 1995; Markert et al., 2001; Pozzi et al., 2011) and even in vivo turnover (McLendon and Radany, 1978; Parsell and Sauer, 1989) , the data presented here suggest that local stabilization of flexible parts of a protein may represent a general mechanism by which resistance to autolysis or proteolysis can be achieved, in particular, when the cleavage sites need to remain untouched. In any case, these variants represent invaluable tools to study the impact of autolysis on both in vivo efficacy and toxicity.
